Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT was delisted on the 31st of December, 2020.
1 hedge funds and large institutions have $0 invested in Bristol-Myers Squibb Company Contingent Value Rights in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $5.52M → $0 (-$5.52M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JCI
Jet Capital Investors
New York
|
-$5.52M |
BMY.RT Hedge Fund Activity: Q2 2023 in Review
1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q2 2023, worth a combined $0 — down 100% from $5.52M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BMY.RT and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Jet Capital Investors, exiting entirely with an estimated $5.52M sold.
- 1 institutional investor held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q2 2023, down from 2 in Q1 2023.
- Funds reported $0 of Bristol-Myers Squibb Company Contingent Value Rights stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q2 2023 and 1 closed out, a net change of -1 holder.
- The largest Bristol-Myers Squibb Company Contingent Value Rights seller in Q2 2023 was Jet Capital Investors, an estimated $5.52M sold.
Based on aggregated 13F filings for Q2 2023.